文献速递肝病

代谢功能障碍相关脂肪性肝病、心血管代谢危险因素数量及其纵向变化引发的心血管风险:一项全国性队列研究

Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2024-12-31

基于全国健康筛查数据纳入2009年基线无心血管疾病的20-79岁成人7,292,497例,中位随访12.3年发生220,088例新发心血管事件。MASLD存在与心血管疾病发病率升高相关;MASLD患者心血管代谢危险因素数量每增加1个,心血管疾病风险比为1.18(95%CI 1.18-1.19);随访期间新发MASLD与心血管疾病风险升高相关(HR 1.28,95%CI 1.25-1.31),MASLD消退与风险降低相关(HR 0.84,95%CI 0.82-0.86)。

要点

  • MASLD存在与心血管疾病发病率升高相关,风险随心血管代谢危险因素数量增加而逐渐升高。
  • 随访期间新发MASLD与心血管疾病风险升高相关(HR 1.28,95%CI 1.25-1.31)。
  • 随访期间MASLD消退与心血管疾病风险降低相关(HR 0.84,95%CI 0.82-0.86)。

核心结论

  • MASLD状态、心血管代谢危险因素数量及其纵向变化均与新发心血管疾病风险相关。
  • 作者认为准确识别这些标志物可能有助于MASLD相关心血管疾病风险的个体化管理。

研究设计与样本

  • 基于全国健康筛查数据的队列研究,纳入2009年基线检查时无过量饮酒、无合并肝病且无既往心血管疾病的20-79岁成人(N=7,292,497)。
  • 按MASLD状态分类,MASLD患者按符合的心血管代谢危险因素数量(1-5)进一步分类。
  • 2011年接受随访检查者(N=4,198,672)按基线与随访MASLD状态分类,持续MASLD者按基线与随访心血管代谢危险因素数量组合进一步分类。
  • 采用多变量校正Cox模型评估新发心血管疾病风险。

主要发现

  • 中位随访12.3年期间发生220,088例新发心血管事件。
  • MASLD存在与心血管疾病发病率升高相关。
  • MASLD患者中心血管疾病风险随心血管代谢危险因素数量增加而逐渐升高(每增加1个;HR 1.18,95%CI 1.18-1.19)。
  • 随访期间新发MASLD与心血管疾病风险升高相关(HR 1.28,95%CI 1.25-1.31)。
  • 随访期间MASLD消退与心血管疾病风险降低相关(HR 0.84,95%CI 0.82-0.86)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with incident cardiovascular disease (CVD). However, CVD risk could vary across and within individuals with MASLD. We investigated the cardiovascular implications of MASLD, cardiometabolic risk factor count, and their longitudinal changes. METHODS: From nationwide health screening data, we included adults aged 20-79 years without increased/excessive alcohol intake, concomitant liver diseases, and prior CVD at baseline examination in 2009 (N = 7,292,497). Participants were classified according to MASLD status; those with MASLD were further categorized by their count of qualifying cardiometabolic risk factors (1-5). Individuals who underwent follow-up examinations in 2011 (N = 4,198,672) were additionally classified according to their baseline and follow-up MASLD status; those with persistent MASLD were further categorized by combination of baseline and follow-up cardiometabolic risk factor counts. The risk of incident CVD was assessed using multivariable-adjusted Cox model. RESULTS: Over a median follow-up of 12.3 years, 220,088 new CVD events occurred. The presence of MASLD was associated with higher incidence of CVD. Among participants with MASLD, the risk of CVD increased gradually with higher cardiometabolic risk factor count (per 1-higher; hazard ratio [HR] 1.18, 95% confidence interval [CI] 1.18-1.19). The development of MASLD during follow-up was associated with higher risk of CVD (HR 1.28, 95% CI 1.25-1.31), whereas the regression of MASLD was associated with lower risk of CVD (HR 0.84, 95% CI 0.82-0.86). Among individuals with persistent MASLD, gaining and losing cardiometabolic risk factor count during follow-up were associated with elevated and reduced risk of CVD, respectively. DISCUSSION: MASLD status, cardiometabolic risk factor count, and their longitudinal changes were all associated with the risk of incident CVD. Accurate identification of these markers may facilitate personalized management of MASLD-related CVD risk.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lee HH, Lee HA, Kim EJ, et al. Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study. Am J Gastroenterol. 2024. PMID: 39787330. doi:10.14309/ajg.0000000000003274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。